AbbVie Presents Long-Term Safety and Efficacy Data for Rinvoq in Atopic Dermatitis

AbbVie today presented three-year long-term safety and efficacy data for Rinvoq (upadacitinib) in patients with moderate-to-severe atopic dermatitis at a major dermatology congress. The data showed that Rinvoq maintained significant improvements in skin clearance and itch reduction over 152 weeks of treatment.